Here, the authors provide an overview of PTCL, review the role of HDAC inhibitors as anticancer agents, discuss romidepsin use in PTCL, and highlight considerations for advanced practitioners (including the management of side effects). Here, HDAC9 is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.